2011年8月31日，星期三
AstraZeneca today announced that the sale of its Astra Tech business to DENTSPLY International Inc. for approximately $1.8 billion in cash has completed. The transaction closed on 31 August 2011.
The gain will be recorded as ‘other operating income’ in AstraZeneca’s third quarter profit and loss account and will be considered a ‘significant item’ to be excluded from Core financial measures. As a result, there will be no impact on the Company’s full year 2011 guidance for Core earnings per share.
As announced at AstraZeneca’s second quarter and half year results, net proceeds from the disposal of Astra Tech, will be used to augment the share repurchase programme to levels above the current $4 billion target. Now that the transaction is complete, the Company estimates that net share repurchases could increase to $5 billion in 2011; with repurchases from any remaining balance of the Astra Tech proceeds to be completed in 2012.
注释编辑
About Astra Tech
Astra Tech AB is a global leader in dental and healthcare (urological and surgical) products, services and support. An innovation-driven company since its foundation in 1948, Astra Tech has continually developed market-leading solutions to meet healthcare needs based on user and medical community input. Ongoing research and development is aimed at finding new ways to support caregivers and improve quality of life for patients worldwide.
Astra Tech headquarters are located in Mölndal, Sweden, with production facilities in Sweden and North America. The company is represented globally with marketing subsidiary presence in 21 countries and selected local distribution partners. Astra Tech has 2,200 employees worldwide.
About DENTSPLY
DENTSPLY designs, develops, manufactures and markets a broad range of professional dental products including dental implants, endodontic instruments and materials, orthodontic appliances, restorative materials, preventive materials and devices, and prosthetic materials and devices. The Company distributes its professional dental products in over 120 countries under some of the most well-established brand names in the industry. DENTSPLY is committed to the development of innovative, high quality, cost-effective new products for the professional dental market.
关于阿斯利康欧洲杯微信买球
欧洲杯微信买球阿斯利康（Astrazeneca）是一家全球创新驱动的生物制药业务，主要关注胃肠道，心血管，神经科学，呼吸和炎症，肿瘤学和感染性疾病的处方药的发现，开发和商业化。欧洲杯微信买球阿斯利康在100多个国家 /地区运营，其创新药物被全球数百万患者使用。有关更多信息，请访问：www.vivelima.com
CONTACTS
媒体查询
Esra Erkal-Paler +44 20 7604 8030（24小时）
阿比盖尔男爵+44 20 7604 8034（24小时）
Investor Enquiries UK
Jonathan Hunt +44 20 7604 8122 mob: +44 7775 704032
Karl Hård +44 20 7604 8123 mob: +44 7789 654364
Nicklas Westerholm +44 20 7604 8124 mob: +44 7585 404950
Investor Enquiries US
Ed Seage +1 302 886 4065 mob: +1 302 373 1361
Jorgen Winroth +1 212 579 0506 mob: +1 917 612 4043